Loading provider…
Loading provider…
Infectious Disease Physician in Nashville, TN
NPI: 1134211543Primary Practice Location
VANDERBILT UNIVERSITY MEDICAL CENTER
2200 Childrens Way, Nashville, TN
Primary Employer
Vanderbilt Medical Group
vanderbilthealth.com
HQ Phone
Get MD David's Phone Numberphone_androidMobile
Get MD David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 16 | 28 |
| 2 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 14 |
Authors: Cindi, Zinhle, Kawuma, Aida N, Maartens, Gary, Bradford, Yuki, Venter, Francois, Sokhela, Simiso, Chandiwana, Nomathemba, Wasmann, Roeland E, Denti, Paolo, Wiesner, Lubbe, Ritchie, Marylyn D, Haas, David W, Sinxadi, Phumla
Journal: J Infect Dis
Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.
Authors: Spyros Kalams, Gregory Robbins, Richard Pollard, Todd Hulgan
Publication Date: 2011-07-28
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: Doravirine 100 Mg, DRUG: Integrase strand transfer inhibitors, DRUG: Tenofovir alafenamide/emtricitabine, DRUG: tenofovir disproxil fumarate/emtricitabine
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Exegi Pharma, LLC
Intervention / Treatment: DRUG: Placebo, DRUG: Visbiome Extra Strength
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: Lamivudine, DRUG: Dolutegravir